please read the following thoroughly, as it contains important information.
At White Oak Psychiatric Services (WOPS), we are committed to providing high-quality, evidence-based care for individuals diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) and related conditions. As the regulatory landscape surrounding stimulant medications—including Adderall, Vyvanse, Ritalin, and Concerta—continues to evolve, we believe it is essential to remain transparent about our prescribing practices and policies.
Across the country, new federal and state regulations have been introduced in response to concerns around misuse, diversion, and overprescribing of controlled substances. Unfortunately, these rules often vary by jurisdiction, are inconsistently applied, or remain in draft form—creating significant challenges for both healthcare providers and patients.
Despite this uncertain regulatory environment, WOPS remains dedicated to offering responsible stimulant prescribing for individuals with a legitimate clinical need. To ensure our approach is safe, ethical, and compliant, we have established the following prescribing policies:
WOPS Stimulant Medication Policy
Our prescribing practices are aligned with current clinical best practices and regulatory expectations, and focus on four key areas:
1. Diagnostic Accuracy & Ongoing Monitoring
- All patients being considered for stimulant medication must undergo objective psychometric or neuropsychiatric testing to confirm an ADHD diagnosis. This may be completed through WOPS or an approved external provider.
- If prior testing has been completed elsewhere, we encourage patients to provide those records for review.
- While routine urine drug screening is not standard for all patients, it may be required when clinically indicated to support safe prescribing.
2. Controlled & Responsible Prescribing
- We follow strict internal dosage and quantity guidelines for all stimulant prescriptions.
- Our providers regularly review prescribing patterns to ensure adherence to safety and regulatory standards.
- We use Prescription Drug Monitoring Programs (PDMPs) to prevent duplicate or overlapping prescriptions from multiple sources.
- No early refills will be issued under any circumstances.
3. Regular In-Person Visits & Follow-Up
- An initial in-person evaluation is required before initiating any stimulant medication.
- After starting treatment, patients must be seen in person at least once per year.
- Ongoing follow-up is required every 90 days (3 months) to continue receiving prescriptions. Refills will not be provided if follow-up appointments are missed or delayed.
4. Geographic & Licensing Restrictions
- Stimulant prescriptions will only be sent to pharmacies located in Missouri or Kansas, where our providers are currently licensed.
- Patients must reside in Missouri or Kansas, and be treated by a provider licensed in their state of residence.
- We do not prescribe stimulant medications across state lines outside of our licensed jurisdictions.
Our Commitment
We understand that these policies may feel restrictive, but they are designed to protect patient safety, ensure compliance with changing laws, and preserve access to medications for those who truly benefit from them.
WOPS remains committed to providing compassionate, compliant, and effective care to every patient we serve.
If you have questions about these policies or how they may affect your treatment plan, please don’t hesitate to contact our office.